OmniAb, Inc.

OABI Healthcare Biotechnology

OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024.

Revenue
+78.3%
EPS
+14.3%
Free cash flow
+206.3%

Quarter to September 2026, against a year earlier

5.02 0.19 +3.93%
Market cap
$704.5M
P/E
0.0×
Fwd P/E
−14.0×
Dividend yield
—
F-score
2/9
Altman Z
2.45
Beneish M
−2.40
Dividend safety
n/a

OmniAb, Inc. (OABI) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, OmniAb, Inc. (OABI) trades at a EV/Sales of 14.5×. Over the past ten years it has ranged from 0.0× (December 2022) to 22.7× (April 2024); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 8.4× (27.10%)
FY2024 11.5× (26.84%)
FY2023 15.7× 346.10%
FY2022 3.5× —
FY2021 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 14.4× 108.40%
Jun 2026 6.9× 30.88%
Mar 2026 5.3× (37.12%)
Dec 2025 8.4× 42.28%
15 more quarters

Against its own ten years

Low 0.0× High 22.7×
Ten-year median 6.1×
Current reading's percentile 77

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on OABI